Literature DB >> 24197083

[Neoadjuvant, inductive or adjuvant chemotherapy of bladder cancer].

C-H Ohlmann1, M De Santis.   

Abstract

Perioperative chemotherapy is a standard treatment for patients with muscle-invasive bladder carcinoma undergoing radical cystectomy; however, direct comparisons of neoadjuvant and adjuvant chemotherapy are lacking. Evidence-based data and implementation into daily clinical practice favor neoadjuvant chemotherapy; nevertheless, neoadjuvant chemotherapy is still underused in daily practice compared to adjuvant chemotherapy. If neoadjuvant chemotherapy has not been used and patients are fit enough to receive cisplatin, adjuvant chemotherapy should be considered in patients with pT3-pT4 and/or lymph node metastases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24197083     DOI: 10.1007/s00120-013-3249-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  30 in total

Review 1.  Defining optimal therapy for muscle invasive bladder cancer.

Authors:  Harry W Herr; Zohar Dotan; S Machele Donat; Dean F Bajorin
Journal:  J Urol       Date:  2007-02       Impact factor: 7.450

Review 2.  Neoadjuvant chemotherapy for invasive bladder cancer.

Authors:  Guru Sonpavde; Cora N Sternberg
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

3.  MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

Authors:  Andreas-Claudius Hoffmann; Peter Wild; Christina Leicht; Simone Bertz; Kathleen D Danenberg; Peter V Danenberg; Robert Stöhr; Michael Stöckle; Jan Lehmann; Martin Schuler; Arndt Hartmann
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

4.  Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.

Authors: 
Journal:  Eur Urol       Date:  2005-04-25       Impact factor: 20.096

5.  Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC.

Authors:  R Millikan; C Dinney; D Swanson; P Sweeney; J Y Ro; T L Smith; D Williams; C Logothetis
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

6.  Role of lymph node density in predicting survival of patients with lymph node metastases after radical cystectomy: a multi-institutional study.

Authors:  Takahiro Osawa; Takashige Abe; Nobuo Shinohara; Toru Harabayashi; Ataru Sazawa; Kanako Kubota; Yoshihiro Matsuno; Takeshi Shibata; Yuichiro Shinno; Shinji Kamota; Keita Minami; Shigeo Sakashita; Akira Kumagai; Tatsuya Mori; Katsuya Nonomura
Journal:  Int J Urol       Date:  2008-12-12       Impact factor: 3.369

7.  Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer.

Authors:  Michael P Porter; Matthew C Kerrigan; Bonnie M K Donato; Scott D Ramsey
Journal:  Urol Oncol       Date:  2009-05-17       Impact factor: 3.498

8.  Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience.

Authors:  S Machele Donat; Ahmad Shabsigh; Caroline Savage; Angel M Cronin; Bernard H Bochner; Guido Dalbagni; Harry W Herr; Matthew I Milowsky
Journal:  Eur Urol       Date:  2008-07-14       Impact factor: 20.096

9.  Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma.

Authors:  Lucian R Chirieac; Justine A Barletta; Beow Y Yeap; William G Richards; Tamara Tilleman; Raphael Bueno; Elizabeth H Baldini; John Godleski; David J Sugarbaker
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544

Review 10.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

Authors: 
Journal:  Lancet       Date:  2003-06-07       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.